Tags : live

Merck & Co’s Ervebo (Ebola Zaire Vaccine, Live) Receives Approval

Shots: The Ervebo has received approval in DRC, Burundi, Ghana, and Zambia, following the implementation of the WHO’s Roadmap for introduction & roll‐out of Merck’s rVSV-ZEBOV Ebola virus vaccine in African countries  The 4 countries have licensed an Ebola vaccine within 90 days after WHO prequalification with its anticipated registration in other African countries in […]Read More

Merck’s Ervebo [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Receives EC’s Conditional

Shots: The EC has granted conditional marketing authorization to Ervebo for active immunization of individuals aged ≥ 18yrs. to protect against Ebola virus disease (EVD) caused by Zaire Ebola virus The approval allows Merck to initiate the manufacturing of licensed doses in Germany with its anticipated availability in Q3’20. Additionally, Merck has submitted prequalification status […]Read More